Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
CSE:ZEAL
Price:
627 DKK
1.87%
Market Closed
Updated:
Jun 1, 2024
Zealand Pharma A/S
Cash from Financing Activities
|
Zealand Pharma A/S
Cash from Financing Activities Peer Comparison
Comparables:
GMAB
ASND
B
BAVA
BIOPOR
SANION
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash from Financing Activities
kr2.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Cash from Financing Activities
-kr590m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash from Financing Activities
€135m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash from Financing Activities
kr140.9m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash from Financing Activities
kr37.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Saniona AB
STO:SANION
|
Cash from Financing Activities
-kr8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Zealand Pharma A/S's Cash from Financing Activities?
Cash from Financing Activities
2.7B
DKK
2.7B
DKK
Based on the financial report for Mar 31, 2024, Zealand Pharma A/S's Cash from Financing Activities amounts to 2.7B DKK.
What is Zealand Pharma A/S's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
27%
27%
Over the last year, the Cash from Financing Activities growth was 335%. The average annual Cash from Financing Activities growth rates for Zealand Pharma A/S have been 27% over the past three years .
You don't have any saved screeners yet
